Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Haemophilia. 2009 Mar;15(2):552–558. doi: 10.1111/j.1365-2516.2008.01935.x

Figure 1. Impact of HAART on End-Stage Liver Disease (ESLD)-Free Survival in Hemophilic Men with HIV/HCV Co-Infection.

Figure 1

The median time to ESLD among HIV-infected HAART-treated hemophilic men (Group 1) (solid line) was 30.3 years, significantly longer than in HIV-infected non-HAART-treated hemophilic men (Group 2) (bold dotted line), 20.0 years, p = 0.043; but not different from time to ESLD in HIV(−) hemophilic men (Group 3) (dashed line), 20.2 years, p = 0.059.